Simple Summary In this review, we examined relevant clinical trial results with immune
checkpoint inhibitors in patients with metastatic urothelial cancer. We also focused on the …

In the last decade, immunotherapy has revolutionized the treatment landscape of several
hematological and solid malignancies, reporting unprecedented response rates …

Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide.
Metastatic UC has been historically associated with poor prognosis, with a median overall …

Simple Summary Urothelial bladder cancer (BC) is one of the most fatal cancers, with a
dismal five-year survival rate of 5% in patients with metastatic disease. Clinically relevant …

Abstract Context Immune checkpoint inhibitors (ICIs) have reported durable responses in
selected groups of patients with metastatic urothelial carcinoma (mUC). However …

Immune checkpoint inhibitors (ICIs) have led to a significant change in the treatment of
urological tumors where several agents are currently approved. Yet, most patients …

Immunotherapy of bladder cancer is known to have favorable effects, although it is difficult to
determine which patients will show a good response because of the different tumor …

Background: Bladder cancer (BC) is one of the most common malignant urological cancer in
the world. Because of its characteristic of easy-recurrence and muscle-invasive, advances in …

Objective: Immune checkpoint inhibitors (ICIs) have recently demonstrated promising
performance in improving the prognosis of urological cancer patients. The goal of this meta …

Objective Numerous epidemiological investigations have explored the impact of body
composition on the effectiveness of immune checkpoint inhibitors (ICIs) in urological …